萨库比特里尔/瓦尔萨坦作为心力衰竭患者标准治疗的补充剂:一项随机对照试验
Reevanshi Dhawan1, Rakesh Mittal1, Ashwani Kumar2
1Department of Pharmacology, PGIMS, Rohtak 124001, Haryana, India.
World journal of experimental medicine
|January 7, 2026
概括
萨库比特里尔/瓦尔沙坦显著改善了心力衰竭生物标志物,减少了炎症,提高了患者的生活质量. 这项研究支持其作为心力衰竭 (HF) 的有效补充疗法.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 萨库比特里尔/瓦尔萨坦是一种血管激素受体无素抑制剂 (ARNI),结合了瓦尔萨坦和萨库比特里尔.
- 在心力衰竭 (HF) 中,RNAs 通过阻断血管激素-II 和抑制 natriuretic 分解是有益的.
研究的目的:
- 评估萨库比特里尔/瓦尔萨坦对NT-pro BNP,hs-CRP和高血压患者的生活质量的影响.
- 评估sacubitril/valsartan作为标准HF治疗的补充剂.
主要方法:
- 一个为期12周的随机对照试验,比较sacubitril/valsartan加标准治疗与单独标准治疗.
- 主要终点:NT-pro BNP水平的变化. 二级终点:hs-CRP水平,WHOQOL-BREF得分,以及不良事件.
主要成果:
- 与标准治疗相比,萨库比特里尔/瓦尔沙坦显著降低了NT-pro BNP和hs-CRP水平.
- 萨库比特里尔/瓦尔沙坦组显示生活质量得到了更大的改善 (WHOQOL-BREF评分).
- 在这两组中都没有报告任何重大不良事件.
结论:
- 萨库比特里尔/瓦尔萨坦有效改善HF生物标志物,炎症和生活质量.
- 它是标准HF治疗的安全有效补充.
- 需要进一步研究关于死亡率和心脏重塑的长期益处.
更多相关视频
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.9K
09:11Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
Published on: September 22, 2014
12.4K
相关概念视频
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:22Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
01:22Heart Failure Drugs: Diuretics
789
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
789
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
433
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
433
01:22Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758